American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Phase 1/2 Dose Expansion of a Trial Investigating Bendamustine and Pomalidomide with Dexamethasone in Patients with RRMM

ASCO 2017 – Multiple Myeloma

The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

Doxorubicin Hydrochloride, Lenalidomide, and Dexamethasone versus Bortezomib, Lenalidomide, and Dexamethasone Prior to Scheduled Stem-Cell Transplant in Newly Diagnosed Myeloma

ASCO 2017 – Multiple Myeloma

The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma. Read More ›

Lenalidomide Induction and Maintenance Therapy for Transplant-Eligible Myeloma Patients: Results of the Myeloma XI Study

ASCO 2017 – Multiple Myeloma

The Myeloma XI Study analyzed lenalidomide induction and maintenance therapy in transplant-eligible patients with myeloma. Read More ›

Randomized, Double-Blind Phase 3 Study of Ibrutinib versus Placebo in Combination with Corticosteroids in Patients with New-Onset cGVHD

ASCO 2017 – CLL

Researchers are evaluating ibrutinib with prednisone as a potential treatment option for patients with newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD). Read More ›

Pembrolizumab plus Lenalidomide and Low-Dose Dexamethasone for RRMM: Efficacy and Biomarker Analyses

ASCO 2017 – Multiple Myeloma

Results from the KEYNOTE-023 trial show that the combination of pembrolizumab plus lenalidomide and low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T-Cell Therapy for RRMM: Updated Results

ASCO 2017 – Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy with bb2121 shows a promising new treatment paradigm in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

Pomalidomide + Low-Dose Dexamethasone after Lenalidomide-Based Second-Line Treatment in Patients with RRMM: Analysis of Progression-Free Survival by Level of Disease Control

ASCO 2017 – Multiple Myeloma

Pomalidomide plus low-dose dexamethasone used as third-line therapy improves survival outcomes in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide versus Placebo Maintenance After Stem-Cell Transplant for Patients with MM—OS and PFS Adjusted for Treatment Crossover

ASCO 2017 – Multiple Myeloma

This phase 3 study compared lenalidomide maintenance versus placebo after stem-cell transplant in patients with newly diagnosed multiple myeloma, adjusting overall survival (OS) and progression-free survival (PFS) for treatment crossover. Read More ›

Impact of Post-ASCT Maintenance Therapy on Outcomes in Patients with NDMM Using the Large, Prospective Community-Based Connect MM Registry

ASCO 2017 – Multiple Myeloma

Insights from the Connect MM Registry show that lenalidomide maintenance therapy after autologous stem-cell transplant (ASCT) significantly improves progression-free survival and overall survival in patients with newly diagnosed multiple myeloma (NDMM). Read More ›

Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM: Efficacy and Safety Update (POLLUX)

ASCO 2017 – Multiple Myeloma

An update on the POLLUX study has shown that daratumumab, lenalidomide, and dexamethasone improves efficacy outcomes in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

American Society of Clinical Oncology (ASCO)

Page 17 of 33